Altimmune, Inc.
NASDAQ:ALTBiotechnology
Healthcare
$1.39 +3.09%
+$0.08 today
- Market cap
- $270.48M
- Beta
- 0.23
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$0.73
52W Low $2.56High $7.73
Volume 4.69M
Average 3.81M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$67.53M
FY 2025 · Annual
Investing Cash Flow
-$132.47M
FY 2025 · Annual
Financing Cash Flow
$206.84M
FY 2025 · Annual
+1959.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (97.09M) | (84.71M) | (88.45M) | (95.06M) | (88.09M) |
| Depreciation & Amortization | 551K | 493K | 477K | 238K | 112K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (681K) |
| Stock-Based Compensation | 5.52M | 8.1M | 10.64M | 14.39M | 16.08M |
| Change in Working Capital | (251K) | 14.11M | (8.27M) | 4.48M | 6.75M |
| Accounts Receivables | 6.53M | 3.3M | (2.31M) | 1.74M | 2.06M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.42M | 2.77M | (2.73M) | (1.86M) | 2.51M |
| Other Working Capital | (8.21M) | 8.04M | (3.23M) | 4.6M | 2.19M |
| Other Non-Cash Items | 13.03M | (578K) | 9.79M | (3.9M) | (1.7M) |
| Operating Cash Flow | (78.24M) | (62.59M) | (75.81M) | (79.85M) | (67.54M) |
| Capital Expenditures | (12.31M) | (126K) | (47K) | 0 | (11K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (7.59M) | (73.27M) | (88.63M) | (115.73M) | (285.45M) |
| Sales of Investments | 107.43M | 0 | 102.41M | 87.35M | 152.99M |
| Other Investing Activities | (195K) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 87.52M | (73.4M) | 13.73M | (28.39M) | (132.47M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 33.92M |
| Common Stock Issued | 65.04M | 56.35M | 86.6M | 9.99M | 173.73M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 58K | 434K | (496K) | 50K | (709K) |
| Financing Cash Flow | 65.1M | 56.78M | 86.11M | 10.04M | 206.84M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 74.38M | (79.2M) | 24.03M | (98.19M) | 6.83M |
| Free Cash Flow | (90.55M) | (62.71M) | (75.86M) | (79.85M) | (67.55M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$88.1M
+ D&A$112.0K
+ Stock-Based Comp$16.1M
- Deferred Tax-$681.0K
+ Working Capital$6.8M
- Other Non-Cash-$1.7M
= Operating Cash Flow-$67.5M
- Capex-$11.0K
= Free Cash Flow-$67.5M
Analysis
FY2025 free cash flow is -$67.5M. FCF conversion is 76.7% of net income. Operating cash flow was -$67.5M, with capex of -$11.0K. The largest bridge item is Stock-Based Comp at $16.1M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 |
Does ALT generate free cash flow?
Altimmune, Inc. (ALT) generated -$67.55M of free cash flow in fiscal 2025.
How much operating cash flow does ALT produce?
Operating cash flow was -$67.53M, before capital expenditures of $11,000.00.
Continue the stock analysis
Jump to another research area for this company.